ABSTRACT

Osteoarthritis (OA) is a common difficult-to-treat condition where the goal, in the absence of disease-modifying treatments, is to alleviate symptoms such as pain and loss of function. Acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids are common pharmacologic treatments for OA. Antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents under clinical investigation for the treatment of OA. This narrative review describes (and uses schematics to visualize) nociceptive signaling, chronification of pain, and the mechanisms of action (MOAs) of these different analgesics in the context of OA-related pain pathophysiology. Further, the varying levels of efficacy and safety of these agents observed in patients with OA is examined, based on an overview of published clinical data and/or treatment guidelines (when available), in the context of differences in their MOAs.

摘要

骨关节炎 (OA) 是一种常见的难以治疗的疾病，在没有疾病修饰治疗的情况下，其目标是减轻疼痛和功能丧失等症状。对乙酰氨基酚、非甾体抗炎药 (NSAID) 和阿片类药物是 OA 的常见药物治疗方法。针对神经生长因子 (NGF-Abs) 的抗体是一类正在临床研究中用于治疗 OA 的新型药物。这篇叙述性评论描述（并使用示意图来可视化）伤害性信号、疼痛的时间变化以及这些不同镇痛药在 OA 相关疼痛病理生理学背景下的作用机制 (MOA)。此外，检查了这些药物在 OA 患者中观察到的不同水平的有效性和安全性，